|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Bertuccio P, Turati F, Carioli G,
Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends
and predictions in hepatocellular carcinoma mortality. J Hepatol.
67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valery PC, Laversanne M, Clark PJ, Petrick
JL, McGlynn KA and Bray F: Projections of primary liver cancer to
2030 in 30 countries worldwide. Hepatology. 67:600–611. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Kudo M, Merle P, Meyer T, Qin
S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, et al: Lenvatinib plus
pembrolizumab versus lenvatinib plus placebo for advanced
hepatocellular carcinoma (LEAP-002): A randomised, double-blind,
phase 3 trial. Lancet Oncol. 24:1399–1410. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sangro B, Chan SL, Kelley RK, Lau G, Kudo
M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK,
et al: Four-year overall survival update from the phase III
HIMALAYA study of tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. Ann Oncol. 35:448–457. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zongyi Y and Xiaowu L: Immunotherapy for
hepatocellular carcinoma. Cancer Lett. 470:8–17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang Y, Zhang Y, Zhang M, Zhao K, Feng L,
Guan J, Dong R, Liu J, Tian D, Liu M, et al: Combined immunotherapy
for hepatocellular carcinoma: How to maximize immune checkpoint
blockade synergic anti-tumor effect. Crit Rev Oncol Hematol.
189:1040702023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Swierczak A, Ibahim M, Paiva P,
Cann L, Stevenson AW, Crosbie JC, Anderson RL and Rogers PAW:
Synchrotron microbeam radiotherapy evokes a different early tumor
immunomodulatory response to conventional radiotherapy in EMT6.5
mammary tumors. Radiother Oncol. 133:93–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li JX, Su TS, Gong WF, Zhong JH, Yan LY,
Zhang J, Li LQ, He ML, Zhang RJ, Du YQ, et al: Combining
stereotactic body radiotherapy with camrelizumab for unresectable
hepatocellular carcinoma: A single-arm trial. Hepatol Int.
16:1179–1187. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiang CL, Lee FAS, Chan KSK, Lee VWY,
Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, et al:
Survival outcome analysis of stereotactic body radiotherapy and
immunotherapy (SBRT-IO) versus SBRT-alone in unresectable
hepatocellular carcinoma. Liver Cancer. 13:265–276. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiang CL, Chiu KW, Lee FA, Kong FS and
Chan AC: Combined stereotactic body radiotherapy and immunotherapy
versus transarterial chemoembolization in locally advanced
hepatocellular carcinoma: A propensity score matching analysis.
Front Oncol. 11:7988322021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li
JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al: Sequential
transarterial chemoembolisation and stereotactic body radiotherapy
followed by immunotherapy as conversion therapy for patients with
locally advanced, unresectable hepatocellular carcinoma
(START-FIT): A single-arm, phase 2 trial. Lancet Gastroenterol
Hepatol. 8:169–178. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Juloori A, Katipally RR, Lemons JM, Singh
AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, et
al: Phase 1 randomized trial of stereotactic body radiation therapy
followed by nivolumab plus Ipilimumab or nivolumab alone in
advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol
Biol Phys. 115:202–213. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim BH, Park HC, Kim TH, Koh YH, Hong JY,
Cho Y, Sinn DH, Park B and Park JW: Concurrent nivolumab and
external beam radiation therapy for hepatocellular carcinoma with
macrovascular invasion: A phase II study. JHEP Rep. 6:1009912024.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li JX, Deng WX, Huang ST, Lin XF, Long MY,
Zhang J, Su TS, Li LQ, Pang YD, Liang CF, et al: Efficacy and
safety of radiotherapy plus anti-PD1 versus transcatheter arterial
chemoembolization plus sorafenib for advanced hepatocellular
carcinoma: A real-world study. Radiat Oncol. 17:1062022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ning C, Jia J, Zhang X, Sun J, Wang Y, Xue
J, Zhang L, Hou X, Yang X, Sang X, et al: Efficacy and safety of
subsequent radiotherapy in patients with advanced-stage
hepatocellular carcinoma treated with immune checkpoint inhibitors.
Hepatobiliary Surg Nutr. 12:882–897. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ning C, Zhang X, Wang Y, Yang X, Yang X,
Chao J, Xun Z, Xue J, Wang Y, Sun H, et al: Radiation therapy with
combination therapy of immune checkpoint inhibitors and
antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat
Oncol Biol Phys. 118:1461–1471. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tai D, Loke K, Gogna A, Kaya NA, Tan SH,
Hennedige T, Ng D, Irani F, Lee J, Lim JQ, et al: Radioembolisation
with Y90-resin microspheres followed by nivolumab for advanced
hepatocellular carcinoma (CA 209–678): A single arm, single centre,
phase 2 trial. Lancet Gastroenterol Hepatol. 6:1025–1035. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Ji X, Sun J, Zhang A, Jia J, Zhang
T, Li W and Duan X: Stereotactic body radiotherapy combined with
lenvatinib with or without PD-1 inhibitors as initial treatment for
unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol
Phys. 120:1363–1376. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM,
Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, et al: Effects of
stereotactic body radiation therapy plus PD-1 inhibitors for
patients with transarterial chemoembolization refractory. Front
Oncol. 12:8396052022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu S, Yu M, Keane B, Mauro DM, Helft PR,
Harris WP, Sanoff HK, Johnson MS, O'Neil B, McRee AJ and
Somasundaram A: A pilot study of pembrolizumab in combination with
Y90 radioembolization in subjects with poor prognosis
hepatocellular carcinoma. Oncologist. 29:270–e413. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin LW, Yan LY, Ke K, Yang WZ, Lin JQ and
Huang N: Efficacy and safety of transarterial chemoembolization
combined with lenvatinib, programmed death-1 inhibitor, and
iodine-125 seed brachytherapy for hepatocellular carcinoma with
portal vein tumor thrombosis. Brachytherapy. 22:858–871. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Li C, Liao W, Huang Y and Wang Z:
A combination of sorafenib, an immune checkpoint inhibitor, TACE
and stereotactic body radiation therapy versus sorafenib and TACE
in advanced hepatocellular carcinoma accompanied by portal vein
tumor thrombus. Cancers (Basel). 14:36192022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L,
Wu J, Fan W and Peng Z: Sintilimab plus bevacizumab combined with
radiotherapy as first-line treatment for hepatocellular carcinoma
with portal vein tumor thrombus: A multicenter, single-arm, phase 2
study. Hepatology. 80:807–815. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raoul JL, Bruix J, Greten TF, Sherman M,
Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G,
Dominguez S, et al: Relationship between baseline hepatic status
and outcome, and effect of sorafenib on liver function: SHARP trial
subanalyses. J Hepatol. 56:1080–1088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamashita T, Kudo M, Ikeda K, Izumi N,
Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, et
al: REFLECT-a phase 3 trial comparing efficacy and safety of
lenvatinib to sorafenib for the treatment of unresectable
hepatocellular carcinoma: An analysis of Japanese subset. J
Gastroenterol. 55:113–122. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kudo M, Ueshima K, Ikeda M, Torimura T,
Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al:
Final results of TACTICS: A randomized, prospective trial comparing
transarterial chemoembolization plus sorafenib to transarterial
chemoembolization alone in patients with unresectable
hepatocellular carcinoma. Liver Cancer. 11:354–367. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kudo M, Ueshima K, Ikeda M, Torimura T,
Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al:
Randomised, multicentre prospective trial of transarterial
chemoembolisation (TACE) plus sorafenib as compared with TACE alone
in patients with hepatocellular carcinoma: TACTICS trial. Gut.
69:1492–1501. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kelley RK, Ryoo BY, Merle P, Park JW,
Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, et al:
Second-line cabozantinib after sorafenib treatment for advanced
hepatocellular carcinoma: A subgroup analysis of the phase 3
CELESTIAL trial. ESMO Open. 5:e0007142020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle
PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al:
Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased alpha-fetoprotein
concentrations (REACH-2): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 20:282–296. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yau T, Park JW, Finn RS, Cheng AL,
Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, et
al: Nivolumab versus sorafenib in advanced hepatocellular carcinoma
(CheckMate 459): A randomised, multicentre, open-label, phase 3
trial. Lancet Oncol. 23:77–90. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kudo M, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Updated efficacy and safety of KEYNOTE-224: A phase II study
of pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib. Eur J Cancer. 167:1–12. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q, Cao M, Lei L, Yang F, Li H, Yan X,
He S, Zhang S, Teng Y, Xia C and Chen W: Burden of liver cancer:
From epidemiology to prevention. Chin J Cancer Res. 34:554–566.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kelley RK, Rimassa L, Cheng AL, Kaseb A,
Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V,
et al: Cabozantinib plus atezolizumab versus sorafenib for advanced
hepatocellular carcinoma (COSMIC-312): A multicentre, open-label,
randomised, phase 3 trial. Lancet Oncol. 23:995–1008. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang SP, Gergich K, Lubiniecki GM, de
Alwis DP, Chen C, Tice MAB and Rubin EH: Pembrolizumab KEYNOTE-001:
An adaptive study leading to accelerated approval for two
indications and a companion diagnostic. Ann Oncol. 28:1388–1398.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB,
Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al:
Efficacy and safety of nivolumab plus ipilimumab in patients with
advanced hepatocellular carcinoma previously treated with
sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol.
6:e2045642020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Y, Xiong L, Li M, Jiang P, Wang J and
Li C: Advances in radiotherapy and immunity in hepatocellular
carcinoma. J Transl Med. 21:5262023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haikerwal SJ, Hagekyriakou J, MacManus M,
Martin OA and Haynes NM: Building immunity to cancer with radiation
therapy. Cancer Lett. 368:198–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen MF, Chen PT, Hsieh CC and Wang CC:
Effect of proton therapy on tumor cell killing and immune
microenvironment for hepatocellular carcinoma. Cells. 12:3322023.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Frey B, Rubner Y, Wunderlich R, Weiss EM,
Pockley AG, Fietkau R and Gaipl US: Induction of abscopal
anti-tumor immunity and immunogenic tumor cell death by ionizing
irradiation-implications for cancer therapies. Curr Med Chem.
19:1751–1764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bernstein MB, Krishnan S, Hodge JW and
Chang JY: Immunotherapy and stereotactic ablative radiotherapy
(ISABR): A curative approach? Nat Rev Clin Oncol. 13:516–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Friedman D, Baird JR, Young KH, Cottam B,
Crittenden MR, Friedman S, Gough MJ and Newell P: Programmed cell
death-1 blockade enhances response to stereotactic radiation in an
orthotopic murine model of hepatocellular carcinoma. Hepatol Res.
47:702–714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chiang CL, Chan ACY, ChiuKW H and Kong FS:
Combined stereotactic body radiotherapy and checkpoint inhibition
in unresectable hepatocellular carcinoma: A potential synergistic
treatment strategy. Front Oncol. 9:11572019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dawood ZS, Brown ZJ, Alaimo L, Lima HA,
Shaikh C, Katayama ES, Munir MM, Moazzam Z, Endo Y, Woldesenbet S
and Pawlik TM: Comparison of tumor response and outcomes of
patients with hepatocellular carcinoma after multimodal treatment
including immune checkpoint inhibitors-a systematic review and
meta-analysis. HPB (Oxford). 26:618–629. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meyers BM, Knox JJ, Liu DM, McLeod D,
Ramjeesingh R, Tam VC and Lim HJ: The evolution of immune
checkpoint inhibitor combinations in advanced hepatocellular
carcinoma-A systematic review. Cancer Treat Rev. 118:1025842023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tian C, Yu Y, Wang Y, Yang L, Tang Y, Yu
C, Feng G, Zheng D and Wang X: Neoadjuvant immune checkpoint
inhibitors in hepatocellular carcinoma: A meta-analysis and
systematic review. Front Immunol. 15:13528732024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xie E, Yeo YH, Scheiner B, Zhang Y,
Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi
CAM, et al: Immune checkpoint inhibitors for child-pugh class B
advanced hepatocellular carcinoma: A systematic review and
meta-analysis. JAMA Oncol. 9:1423–1431. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Higgins K, Hu C, Ross H, Jabbour S, Kozono
D, Owonikoko T, Dib EG, Brownstein JM, Kuzma C, Kotecha R, et al:
Concurrent chemoradiation±atezolizumab (atezo) in limited-stage
small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance
LU005. Int J Radiat Oncol Biol Phys. 120:S22024. View Article : Google Scholar
|
|
54
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gunderson AJ and Young KH: Exploring
optimal sequencing of radiation and immunotherapy combinations. Adv
Radiat Oncol. 3:494–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Young KH, Baird JR, Savage T, Cottam B,
Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS,
et al: Optimizing timing of immunotherapy improves control of
tumors by hypofractionated radiation therapy. PLoS One.
11:e01571642016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Abou-Alfa GK, Lau G, Kudo M, Chan SL,
Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De
Toni EN, et al: Tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. NEJM Evid. 1:EVIDoa21000702022.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mosele MF, Westphalen CB, Stenzinger A,
Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R,
Krämer A, et al: Recommendations for the use of next-generation
sequencing (NGS) for patients with advanced cancer in 2024: A
report from the ESMO precision medicine working group. Ann Oncol.
35:588–606. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kumar S, Nadda N, Quadri A, Kumar R, Paul
S, Tanwar P, Gamanagatti S, Dash NR, Saraya A, Shalimar and Nayak
B: Assessments of TP53 and CTNNB1 gene hotspot mutations in
circulating tumour DNA of hepatitis B virus-induced hepatocellular
carcinoma. Front Genet. 14:12352602023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bernicker E: Next-Generation sequencing
and immunotherapy biomarkers: A medical oncology perspective. Arch
Pathol Lab Med. 140:245–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cui Y, Li B, Pollom EL, Horst KC and Li R:
Integrating radiosensitivity and immune gene signatures for
predicting benefit of radiotherapy in breast cancer. Clin Cancer
Res. 24:4754–4762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jang BS and Kim IA: A radiosensitivity
gene signature and PD-L1 predict the clinical outcomes of patients
with lower grade glioma in TCGA. Radiother Oncol. 128:245–253.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon J: Sustained
efficacy of adjuvant immunotherapy with cytokine-induced killer
cells for hepatocellular carcinoma: An extended 5-year follow-up.
Cancer Immunol Immunother. 68:23–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen L, Zhang R, Lin Z, Tan Q, Huang Z and
Liang B: Radiation therapy in the era of immune treatment for
hepatocellular carcinoma. Front Immunol. 14:11000792023. View Article : Google Scholar : PubMed/NCBI
|
